AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28357969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 25586864 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG/EE patch (one patch weekly for three consecutive weeks, followed by a patch-free week for 13 cycles)
Number of subjects: 1273
Study 25586864 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive for six cycles followed by seven LNG/EE patch cycles
Number of subjects: 1273
Study 24099944 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-gram language model (LM)
Number of subjects: 0
Study 24099944 — intervention group
Group type: COMPARATOR
Intervention: 3-trial ERP classification
Number of subjects: 0
Study 21372210 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg daily
Number of subjects: 89
Study 21372210 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 1.75 mg daily
Number of subjects: 89
Study 21372210 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.25 mg daily
Number of subjects: 89
Study 21372210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 18834823 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative red blood cell transfusions
Number of subjects: 550
Study 18834823 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum white blood cell count
Number of subjects: 550
Study 18834823 — intervention group
Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 550
Study 17278627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive 1
Number of subjects: 36
Study 17278627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive 2
Number of subjects: 36
Study 17278627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive 3
Number of subjects: 36
Study 17278627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive 4
Number of subjects: 36
Study 17278627 — intervention group
Group type: EXPERIMENTAL
Intervention: All 4 bonding agents
Number of subjects: 36
Study 15144613 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent treatment group (group A)
Number of subjects: 90
Study 15144613 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment group (group B)
Number of subjects: 90
Study 11473503 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (MCB) 450-750 mg daily
Number of subjects: 156
Study 11473503 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (IMI) 150-250 mg daily
Number of subjects: 156
Study 11473503 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (IMI)
Number of subjects: 156
Study 11473503 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (MCB)
Number of subjects: 156
Study 9735587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bibliotherapy
Number of subjects: 22
Study 9735587 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control
Number of subjects: 22
Study 8042735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 0.5% via 26-gauge Atraucan spinal needle
Number of subjects: 30
Study 8042735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 0.5% via 29-gauge Spinocan spinal needle
Number of subjects: 30
Study 3191076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 6
Study 3191076 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 6
Study 3191076 — intervention group
Group type: EXPERIMENTAL
Intervention: guanethidine 5% (pretreatment)
Number of subjects: 6
Study 3191076 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol administration to the normal eye
Number of subjects: 6
Study 30793118 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC sealant with additional light curing
Number of subjects: 111
Study 30793118 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC sealant without additional light curing
Number of subjects: 111
Study 30793118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sealant)
Number of subjects: 111
Study 30793118 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sealant groups (A and B)
Number of subjects: 111
Study 28207733 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI) administered for 2 weeks
Number of subjects: 0
Study 25576857 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at 2500 IU/d during caloric restriction (WL-D)
Number of subjects: 76
Study 25576857 — intervention group
Group type: COMPARATOR
Intervention: Placebo during caloric restriction (WL-C)
Number of subjects: 76
Study 25576857 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at 2500 IU/d during weight maintenance (WM-D)
Number of subjects: 76
Study 25576857 — intervention group
Group type: COMPARATOR
Intervention: Placebo during weight maintenance (WM-C)
Number of subjects: 76
Study 25576857 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 76
Study 24961093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglicate eye drops combined with Yupingfeng granules
Number of subjects: 118
Study 24961093 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglicate alone
Number of subjects: 118
Study 21422420 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg/d
Number of subjects: 1014
Study 21422420 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg/d
Number of subjects: 1014
Study 21422420 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg/d plus interferon alfa (IFN-α)
Number of subjects: 1014
Study 19794004 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 57593
Study 19794004 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy including WOSCOPS
Number of subjects: 57593
Study 17068072 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 1 mg/ml
Number of subjects: 9
Study 17068072 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000 U/ml
Number of subjects: 9
Study 17068072 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase or urokinase infusion
Number of subjects: 9
Study 17068072 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical replacements
Number of subjects: 9
Study 15502051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 10 mg
Number of subjects: 300
Study 15502051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 20 mg
Number of subjects: 300
Study 15502051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 30 mg
Number of subjects: 300
Study 15502051 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR 10 mg
Number of subjects: 300
Study 15502051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 11268301 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogen (EE)
Number of subjects: 34
Study 9702441 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 26
Study 9702441 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline plus sham treatment
Number of subjects: 26
Study 9702441 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined electrotherapy and amitriptyline
Number of subjects: 26
Study 8045488 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a 7.5 megaunits/m2 three times weekly for 6 mo (group 1)
Number of subjects: 77
Study 8045488 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a on the same schedule (group 2)
Number of subjects: 77
Study 8045488 — intervention group
Group type: COMPARATOR
Intervention: Untreated (group 3)
Number of subjects: 77
Study 2729165 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplement (10 mg Zn/d as ZnSO4)
Number of subjects: 60
Study 2729165 — intervention group
Group type: COMPARATOR
Intervention: Control (boys with hair Zn greater than 1.68 mumol/g)
Number of subjects: 60
Study 2729165 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplement
Number of subjects: 60
Study 31287332 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 867
Study 31287332 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab 45/90 mg
Number of subjects: 867
Study 31287332 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg
Number of subjects: 867
Study 31189686 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cryoablation, n=25
Number of subjects: 200
Study 31189686 — intervention group
Group type: COMPARATOR
Intervention: Robotic partial nephrectomy, n=25
Number of subjects: 200
Study 27604107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 48
Study 27604107 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 48
Study 26348459 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Pre-Exposure Prophylaxis (PrEP)
Number of subjects: 61
Study 23934374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound (HFU)
Number of subjects: 90
Study 23934374 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact low-frequency ultrasound (NCLFU)
Number of subjects: 90
Study 23934374 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 90
Study 21635363 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier continuous Kangaroo Mother Care (KMC) initiated within 24 hours postbirth
Number of subjects: 72
Study 21635363 — intervention group
Group type: COMPARATOR
Intervention: Later continuous Kangaroo Mother Care (KMC) initiated after complete stabilization (control group)
Number of subjects: 72
Study 18048461 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Vero cell rabies vaccine (PVRV) given at 2, 4 months and 1 year
Number of subjects: 72
Study 18048461 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria, tetanus, whole‐cell pertussis and inactivated poliomyelitis vaccine (DTP‐IPV)
Number of subjects: 72
Study 18048461 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Vero cell rabies vaccine (PVRV) and DTP‐IPV
Number of subjects: 72
Study 16505510 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg twice a day for 12 weeks)
Number of subjects: 18
Study 16505510 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 14655024 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + methotrexate
Number of subjects: 30
Study 14655024 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 30
Study 14655024 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 30
Study 11389705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (with corticosteroids)
Number of subjects: 345
Study 11389705 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (with corticosteroids and azathioprine)
Number of subjects: 345
Study 9303652 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-modulatory nutrition Impact
Number of subjects: 30
Study 9303652 — intervention group
Group type: COMPARATOR
Intervention: Precitene Hiperproteico
Number of subjects: 30
Study 8418030 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 224
Study 8418030 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 224
Study 3531958 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 0
Study 3531958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 31719071 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural catheter (PNC) with continuous infusion of levobupivacaine hydrochloride 0.125% for up to 5 days
Number of subjects: 50
Study 31719071 — intervention group
Group type: COMPARATOR
Intervention: Usual perioperative anaesthesia and postoperative analgesia (Control)
Number of subjects: 50
Study 29408444 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine (10 mM)
Number of subjects: 18
Study 29408444 — intervention group
Group type: COMPARATOR
Intervention: Control (lactated Ringer's solution)
Number of subjects: 18
Study 29408444 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginase inhibited site (5.0 mM BEC and 5.0 mM nor-NOHA)
Number of subjects: 18
Study 27087145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (30 mg oral, once a day)
Number of subjects: 11
Study 27087145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 25060166 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MR imaging (DWI) and proton magnetic resonance spectroscopy (1H-MRS)
Number of subjects: 30
Study 23014081 — intervention group
Group type: EXPERIMENTAL
Intervention: Band and loop (B&L) space maintainers
Number of subjects: 30
Study 23014081 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bonded (DB) space maintainers
Number of subjects: 30
Study 23014081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite (FRC) space maintainers
Number of subjects: 30
Study 20622033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124) at lower dose (4, 4, and 8 mg/kg)
Number of subjects: 30
Study 20622033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124) at higher dose (10, 10, and 20 mg/kg)
Number of subjects: 30
Study 20622033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124)
Number of subjects: 30
Study 17558098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinospora cordifolia as an adjuvant therapy
Number of subjects: 50
Study 17558098 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 50
Study 16623023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sporal 200 mg twice daily for 1 week
Number of subjects: 133
Study 16623023 — intervention group
Group type: EXPERIMENTAL
Intervention: Itracon 200 mg twice daily for 1 week
Number of subjects: 133
Study 16623023 — intervention group
Group type: EXPERIMENTAL
Intervention: Itra 200 mg twice daily for 1 week
Number of subjects: 133
Study 12564659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 216
Study 12564659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 10215286 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-echo score in patients who developed severe MR (10.5 +/- 1.4)
Number of subjects: 117
Study 10215286 — intervention group
Group type: COMPARATOR
Intervention: MR-echo score in patients who did not develop severe MR (8.2 +/- 1.1)
Number of subjects: 117
Study 10215286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior leaflet score in severe MR group (2.9 +/- 0.5)
Number of subjects: 117
Study 10215286 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior leaflet score in severe MR group (2.6 +/- 0.7)
Number of subjects: 117
Study 10215286 — intervention group
Group type: EXPERIMENTAL
Intervention: Commissures score in severe MR group (2.4 +/- 0.8)
Number of subjects: 117
Study 10215286 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvalvular apparatus score in severe MR group (2.6 +/- 0.5)
Number of subjects: 117
Study 10215286 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-echo score cut-off point > or = 10
Number of subjects: 117
Study 8682088 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy plus conventional drug therapy for congestive heart failure
Number of subjects: 111
Study 8682088 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 111
Study 1320131 — intervention group
Group type: COMPARATOR
Intervention: CAV regimen (cyclophosphamide 1000 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 every 3 weeks)
Number of subjects: 86
Study 1320131 — intervention group
Group type: EXPERIMENTAL
Intervention: Menogaril (200 mg/m2 every 4 weeks)
Number of subjects: 86
Study 1320131 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy (etoposide 120 mg/m2 on days 1, 2, and 3 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks)
Number of subjects: 86
Study 1320131 — intervention group
Group type: COMPARATOR
Intervention: CAV
Number of subjects: 86
Study 1320131 — intervention group
Group type: EXPERIMENTAL
Intervention: Menogaril
Number of subjects: 86
Study 6325313 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (bovine fibrinolysin and desoxyribonuclease, no antibiotic)
Number of subjects: 258
Study 6325313 — intervention group
Group type: COMPARATOR
Intervention: Preparation B (clostridiopeptidase and chloramphenicol)
Number of subjects: 258
Study 6325313 — intervention group
Group type: COMPARATOR
Intervention: Preparation C (trypsin and framycetin sulphate)
Number of subjects: 258
Study 31519328 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Specific Instrument (PSI)
Number of subjects: 30
Study 31519328 — intervention group
Group type: COMPARATOR
Intervention: Robotic system
Number of subjects: 30
Study 31519328 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 30
Study 28948366 — intervention group
Group type: EXPERIMENTAL
Intervention: G/P (glecaprevir/pibrentasvir) 300/120 mg once daily for 8 weeks
Number of subjects: 167
Study 28948366 — intervention group
Group type: COMPARATOR
Intervention: OBV/PTV/r (ombitasvir/paritaprevir/ritonavir) 25/150/100 mg for 12 weeks
Number of subjects: 167
Study 28948366 — intervention group
Group type: EXPERIMENTAL
Intervention: G/P (glecaprevir/pibrentasvir) 300/120 mg once daily for 12 weeks
Number of subjects: 167
Study 27138447 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported mammography screening data
Number of subjects: 192
Study 27138447 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported data on mammography
Number of subjects: 192
Study 24721127 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) combined with standard hydration
Number of subjects: 76
Study 24721127 — intervention group
Group type: COMPARATOR
Intervention: Sham preconditioning combined with standard hydration
Number of subjects: 76
Study 23403419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 50 mg
Number of subjects: 48
Study 23403419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline 200 mg
Number of subjects: 48
Study 23403419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23403419 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 48
Study 20171036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 607
Study 20171036 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft (CABG)
Number of subjects: 607
Study 20171036 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stenting (BMS)
Number of subjects: 607
Study 17588292 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived behavioural control
Number of subjects: 203
Study 17588292 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐efficacy
Number of subjects: 203
Study 17588292 — intervention group
Group type: EXPERIMENTAL
Intervention: Locus of control
Number of subjects: 203
Study 16750022 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg x m(‐2) YH‐16
Number of subjects: 60
Study 16750022 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/m(2) YH‐16
Number of subjects: 60
Study 14500805 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (40 microg subcutaneously daily)
Number of subjects: 83
Study 14500805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Parathyroid hormone + Alendronate)
Number of subjects: 83
Study 14500805 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (10 mg daily)
Number of subjects: 83
Study 10768519 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate 45/6.4 mg/kg/day twice-daily (b.d.)
Number of subjects: 324
Study 10768519 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate 40/10 mg/kg/day three-times-daily (t.d.s.)
Number of subjects: 324
Study 10768519 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate twice-daily (b.d.)
Number of subjects: 324
Study 10768519 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate three-times-daily (t.d.s.)
Number of subjects: 324
Study 8620818 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oral acyclovir (600-800 mg/day)
Number of subjects: 20
Study 8620818 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic therapy (group B)
Number of subjects: 20
Study 2666140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim 1 mg as a single daily oral dose for 5 days
Number of subjects: 8
Study 2666140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim in vitro
Number of subjects: 8
Study 2666140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 227420 — intervention group
Group type: EXPERIMENTAL
Intervention: halofenate
Number of subjects: 14
Study 30141699 — intervention group
Group type: EXPERIMENTAL
Intervention: Soong classification for volar locking plate placement
Number of subjects: 6
Study 31223121 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted knowledge translation (KT) intervention delivered through the McMaster Optimal Aging Portal
Number of subjects: 0
Study 31223121 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted knowledge translation (KT) intervention
Number of subjects: 0
Study 31223121 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28032271 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-based treatment for Specific Phobias
Number of subjects: 117
Study 26541919 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1212
Study 26541919 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1212
Study 23799751 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80
Study 23799751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80
Study 23799751 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80
Study 23799751 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oxygen-air mixture)
Number of subjects: 80
Study 21998319 — intervention group
Group type: EXPERIMENTAL
Intervention: TIA patients
Number of subjects: 26
Study 21998319 — intervention group
Group type: COMPARATOR
Intervention: Control subjects without symptomatic cardiovascular disease
Number of subjects: 26